Limits...
A multi-center study of high dose Aldesleukin (Proleukin ® (HD IL-2) + Vemurafenib Zelboraf ® ) therapy in patients with BRAF V600 mutation positive metastatic melanoma (proclivity 01)

View Article: PubMed Central - HTML

No MeSH data available.


Related in: MedlinePlus

Treatment of metastatic melanoma with HD IL-2 immunotherapy and targeted agent vemurafenib.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4288741&req=5

Figure 1: Treatment of metastatic melanoma with HD IL-2 immunotherapy and targeted agent vemurafenib.

Mentions: Adult patients with measurable metastatic or unresectable Stage III melanoma with no prior therapy and a BRAFV600 mutation who are candidates for HD IL-2 are eligible for entry into the first cohort of 135 patients (figure 1). Six weeks of Vemurafenib therapy per package insert precedes up to 2 courses of HD IL-2. Vemurafenib is administered during the outpatient intervals between cycles of HD IL-2 and following completion. A second cohort of up to 50 similar patients already responding or stable with < 18 weeks of Vemurafenib therapy will also be accrued. The study was amended to permit prior anti-PD-1 therapy. The primary endpoint is Complete Response (CR) and near CR at 6 months of therapy.


A multi-center study of high dose Aldesleukin (Proleukin ® (HD IL-2) + Vemurafenib Zelboraf ® ) therapy in patients with BRAF V600 mutation positive metastatic melanoma (proclivity 01)
Treatment of metastatic melanoma with HD IL-2 immunotherapy and targeted agent vemurafenib.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4288741&req=5

Figure 1: Treatment of metastatic melanoma with HD IL-2 immunotherapy and targeted agent vemurafenib.
Mentions: Adult patients with measurable metastatic or unresectable Stage III melanoma with no prior therapy and a BRAFV600 mutation who are candidates for HD IL-2 are eligible for entry into the first cohort of 135 patients (figure 1). Six weeks of Vemurafenib therapy per package insert precedes up to 2 courses of HD IL-2. Vemurafenib is administered during the outpatient intervals between cycles of HD IL-2 and following completion. A second cohort of up to 50 similar patients already responding or stable with < 18 weeks of Vemurafenib therapy will also be accrued. The study was amended to permit prior anti-PD-1 therapy. The primary endpoint is Complete Response (CR) and near CR at 6 months of therapy.

View Article: PubMed Central - HTML

No MeSH data available.


Related in: MedlinePlus